What happens when you pause a Weight-Loss drug? new study investigates brain and behavior changes
NCT ID NCT07387796
First seen Feb 04, 2026 · Last updated Jun 17, 2026 · Updated 24 times
Summary
This study looks at what happens to your brain and body when you briefly stop taking tirzepatide, a medication for blood sugar and appetite. Researchers will track changes in hunger, mood, sleep, and brain activity in 40 adults aged 18-70 who currently take the drug. Participants will be studied at three points: while on the drug, after a 3-4 week pause, and after restarting it for 6-8 weeks. The goal is to understand how stopping and restarting affects health and daily life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBSTANCE USE DISORDERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Center for BrainHealth
Dallas, Texas, 75235, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.